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Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies worldwide with high mortality rates 
and growing incidence in the western world (Jemal et al. 
2011). Although potentially curative surgical treatments 
are available, only a minority of patients with localized 
small tumors are eligible for these therapeutic options. 
Unfortunately, a great percentage of patients are diag-
nosed at an advanced stage of disease (Pinter et al. 2011), 
for whom sorafenib, a multi-kinase inhibitor, is the first 
effective systemic molecular-targeted treatment option 
(Lachenmayer et al. 2010; Llovet et al. 2008).
Sorafenib has been shown to significantly prolong over-
all survival in patients with advanced HCC (Llovet et al. 
2008). However, there are few validated and reliable molec-
ular markers with which to predict patient outcome under 
sorafenib treatment. Several markers that could potentially 
stratify HCC patients according to sorafenib responsiveness 
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Summary
Sorafenib represents the first effective targeted therapy for advanced stage hepatocellular carcinoma (HCC); however, 
adequate patient stratification regarding sorafenib-responsiveness is still missing. Our aim was to analyse the association 
between the pretreatment microRNA profile of HCC and patient survival under sorafenib treatment. Total RNA was 
extracted from diagnostic fine-needle aspiration biopsy (FNAB) cytological smears of 20 advanced stage HCC patients 
collected between June 2008 and July 2012. All patients underwent sorafenib administration after FNA. Clinicopathological 
and survival data were recorded. Fourteen frequently deregulated miRNAs in HCC (miR-17-5p, miR-18a, miR-21, miR-
34a, miR-122, miR-195, miR-210, miR-214, miR-221, miR-222, miR-223, miR-224, miR-140, miR-328) were tested by qRT-
PCR. NormFinder software was used to select proper miR (mir-140) as a reference. Satisfactory amount of total RNA 
was obtained from all the considered samples (mean 10.8 ± 9.3 µg, range 0.2–32.2 µg). Among the analysed miRNAs, high 
miR-214 expression was associated with smaller tumor size (p=0.019), whereas high miR-17-5p expression correlated 
with better Eastern Cooperative Oncology Group performance status (p=0.003). The survival analysis revealed that high 
miR-224 expression was associated with increased progression-free and overall survival (PFS p=0.029; OS p=0.012). 
Pretreatment microRNA profiling, especially miR-224 expression, might serve as an ancillary tool for the better assessment 
of expected survival rates for patients under sorafenib treatment. (J Histochem Cytochem 62:547–555, 2014)
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were investigated recently: PDGFR-β and c-Met were sug-
gested as predictors of prognosis and therapeutic effective-
ness in sorafenib-treated HCC patients (Chu et al. 2013), 
whereas Mcl-1 and pERK expressions were found to be 
associated with overall survival (Personeni et al. 2013). The 
activation of c-Jun N-terminal kinase in HCC patients cor-
related inversely with therapeutic response to sorafenib 
(Hagiwara et al. 2012) and further factors, including serum 
cholinesterase levels (Takeda et al. 2013), plasma VEGF 
concentration changes (Tsuchiya et al. 2014) and VEGF 
and VEGFR gene polymorphisms (Scartozzi et al. 2014) 
were also presented as potential clinical predictors of 
sorafenib sensitivity. Given the high costs and relatively 
high percentage of “non-responders” to sorafenib [disease 
control rates have been indicated at 43% (Llovet et al. 2008) 
and 53% (Cheng et al. 2009)], the identification of potential 
predictive biomarkers represents a challenge for research 
and is of great interest.
MicroRNAs (miRNAs, miRs) are small (19-25 nt), non-
coding, posttranscriptional regulators of gene expression 
commonly dysregulated in tumors. They target both tumor 
suppressor and oncogenic pathways (Gramantieri et al. 
2008; Lujambio and Lowe 2012) and their altered expres-
sion carries great diagnostic and prognostic potential (Calin 
et al. 2005; Lu et al. 2005; Minguez and Lachenmayer 
2011). In addition, miRNAs are highly stable and are reli-
ably detected in archival clinical samples and cytology 
specimens, and are therefore considered to be ideal bio-
marker candidates (Fassina et al. 2012). Several in vitro 
data suggest that miRs can modulate the sensitivity of HCC 
tumor cells to therapy; for example, miR-122 sensitizes 
HCC cells to adriamycin, vincristin (Xu et al. 2011) and 
sorafenib (Bai et al. 2009); miR-34a induces sensitivity to 
sorafenib in human HCC cells (Yang et al. 2013); and miR-
21 induces resistance to interferon-α/5-fluorouracil in HCC 
cells (Tomimaru et al. 2010). Moreover, low miR-21 
expression has been associated with better clinical response 
and overall survival and was suggested as a potential pre-
dictor for the clinical response to IFN-α/5-FU combination 
therapy (Tomimaru et al. 2010).
HCCs at advanced stages are often associated with a 
significantly elevated risk of bleeding; therefore, fine-nee-
dle aspiration biopsy (FNAB) is favored over conventional 
liver biopsy (Fassina et al. 2010). There are few data of 
miRNA expression in FNAB samples. Simonato et al. 
(2013) recently demonstrated that archival cytology smears 
are suitable for obtaining high-quality RNA to be used in 
microRNA expression profiling. To our knowledge, there 
is no report to date on miRNA expression of liver FNAB 
samples, particularly for sorafenib-treated HCCs. Given 
the great predictive potential of miRNAs, our aim was to 
investigate the pretreatment miRNA expression of diag-
nostic, ultrasound-guided FNAB samples of sorafenib-
treated, advanced stage HCC patients and to correlate the 
obtained results with clinical data. We analysed a panel of 
14 miRNAs that are frequently dysregulated in HCCs 
(Karakatsanis et al. 2013; Varnholt et al. 2008). This is the 
first study to reveal a significant association between pre-
treatment miRNA expression of FNAB samples and the 
outcome of sorafenib-treated HCC patients.
Materials & Methods
Patients and Samples
Twenty HCC FNAB samples from the archives of the 2nd 
Department of Pathology, Semmelweis University, 
Budapest, were analysed in this study. In Hungary, sorafenib 
treatment is applicable only after pathological morphologi-
cal confirmation of HCC diagnosis: either histology or 
FNAB sampling is mandatory in order to treat the patients. 
Diagnoses of HCC were established from FNAB samples 
by two expert cytopathologists (BJ and ES) between June 
2008 and July 2012.  Patients were subsequently treated 
with sorafenib at the Department of Oncology, United Saint 
Stephen and Saint Laszlo Hospital and Outpatient Clinics, 
Budapest.
All patients in this study met the following criteria: no 
prior surgery, loco-regional or systemic treatment, no sub-
sequent loco-regional treatment after the end of sorafenib 
therapy, Child-Pugh class A or B, Eastern Cooperative 
Oncology Group (ECOG) performance status ≤1, more than 
3 months survival after diagnosis, available follow-up data 
(follow-up deadline June 2013). Overall survival (OS) was 
defined as the time period from the start of sorafenib ther-
apy until the date of death or end of follow-up. Progression-
free survival (PFS) was defined as the time period between 
sorafenib initiation and progression or end of follow-up. 
Data and material were obtained with permission from the 
Regional Ethical Committee of Semmelweis University (# 
137/2008) following the ethical guidelines of the 1975 
Declaration of Helsinki and with informed consent of the 
patients.
The presence of >2000 well-preserved and well-visual-
ized HCC cells (as observed in 10 fields at 4× magnifica-
tion) was appointed as minimum accepted cellularity. Only 
slides with a proportion of tumor cells >50% and without 
massive necrotic debris were selected (Fig. 1).
Real-time RT-PCR Analysis
RNA Isolation. Total RNA was isolated from archival FNAB 
slides (fixed by Cytofix spray) using RNeasy FFPE Kit 
(Qiagen; Hilden, Germany). Briefly, slides were immersed 
in xylene for 72 hr to remove coverslips. Cells were scraped 
off the slides with sterile disposable knives and transferred 
into 1.5 ml tubes where proteinase K digestion was per-
formed for 12 hr. Further procedures were carried out 
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according to the manufacturer’s instructions, with modifi-
cation for co-purification of miRNA (Doleshal et al. 2008). 
Traces of genomic DNA were removed using Turbo DNase 
digestion (Ambion; Austin, TX) following the supplier’s 
protocol. RNA concentration and quality were measured 
using a NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies Inc.; Wilmington, DE).
Reverse Transcription (RT) and Real-Time PCR (qPCR). The 
following TaqMan MicroRNA Assays (Applied Biosys-
tems; Foster City, CA) were used to determine the levels of 
the selected 14 miRNAs: miR-17-5p (ID:000393), miR-18a 
(ID:002422), miR-21 (ID:000397), miR-34a (ID:000426), 
miR-122 (ID:002245), miR-140 (ID:000462), miR-195 
(ID:000494), miR-210 (ID:000512), miR-214 (ID:002306), 
miR-221 (ID:000524), miR-222 (ID:002276), miR-223 
(ID:002295), miR-224 (ID:002099), miR-328 (ID:000543) 
and U6 (ID:001973). RT and qPCR were performed accord-
ing to manufacturer’s instructions. Briefly, RT was carried 
out using TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems) in a final volume of 7.5 µl containing 
10 ng total RNA. qPCR was performed using TaqMan Uni-
versal PCR Master Mix No AmpErase UNG (Applied Bio-
systems) in a final volume of 10 µl containing 0.65 µl RT 
product using an ABI Prism 7000 Sequence Detection Sys-
tem (Applied Biosystems). Reactions were run in triplicate, 
including no-template controls.
Relative quantification of target miRNA expression was 
performed using 2Cq(ref)-Cq(target) method, with miR-140 as 
the reference. From the candidate reference small RNAs 
(U6, miR-328, miR-140) to be analysed, miR-140 proved 
to be the most stable miRNA in our sample set, as defined 
by the NormFinder application (Andersen et al. 2004). 
Additionally, miR-140 was also used as reference in a pre-
vious study on HCCs (Varnholt et al. 2008).
Statistical Analysis
Statistical analyses were carried out using STATISTICA 
software v11 (StatSoft; Tulsa, OK). Patients were dichoto-
mized into “high miR expression” and “low miR expres-
sion” groups according to the median relative expression of 
a given miR in order to obviate the effects of extreme val-
ues. Associations between miR expression and clinicopath-
ological characteristics were examined using Fisher’s exact 
test. Survival curves were computed using the Kaplan-
Meier method and differences were assessed using the log-
rank test. Multivariate survival analyses were performed 
using the Cox proportional hazards model. P values ≤ 0.05 
were considered statistically significant.
Results
Patient Characteristics and FNAB miR 
Expression
A total of twenty sorafenib-treated patients were included 
in the present analysis. The median age at the time of diag-
nostic aspiration was 68 years (range, 52–82 years), with a 
male:female ratio of 16:4. Patients were mainly Child-Pugh 
Figure 1. Representative image of a hepatocellular carcinoma sample obtained by fine-needle aspiration biopsy. Irregularly shaped 
tumor aggregates with transgressing endothelium can be seen. The image on the right shows a magnified view of the image on the left. 
Scale bars 100 µm.
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class A (16/20), with ECOG performance status 0 (13/20). 
The etiology of the underlying liver disease was predomi-
nantly viral (11/20), and tumor sizes ranged from 1.5 to 
20 cm (median, 5 cm). Tumors were mostly multinodular 
(14/20). Elevated serum alpha-fetoprotein (AFP) levels 
(≥10 ng/ml) were present in 13/20 patients (Table 1). Of the 
20 patients, 15 died during the follow-up period, with 
5 patients still alive at the end of the study. The median fol-
low-up time was 33.6 months, and the median OS and PFS 
for all patients was 6.2 months (95% CI 2.7–9.3 months) and 
5 months (95% CI 3.5–6.5 months), respectively.
A satisfactory amount of total RNA was obtained from 
all considered samples. The mean ± SD RNA yield was 
10.8 ± 9.3 µg (range, 0.2–32.2 µg) with an OD
260/280
 ratio of 
2.0 ± 0.1. The normalized relative expression values of 
miRs are shown in Table 2.
Relationship between Pretreatment miR 
Expression and Clinicopathological Features
Relationships between miR expression and clinicopatho-
logical features, such as age (<68 years / ≥68 years), gender 
(male/female), etiology (viral / other), tumor number (single / 
multinodular), tumor size (≤5cm / >5cm), Child-Pugh 
status (A / B), ECOG status (0 / 1) and AFP levels 
(<10 ng/ml / ≥10 ng/ml), were analysed to identify possible 
associations. Median miR expression values were used to 
divide patients into high and low expression groups.
High miR-214 expression was more frequent in patients 
with smaller tumors (≤5 cm) than in larger ones (>5 cm) 
(80% vs 20%, p=0.019). High miR-17-5p expression was 
more frequent in patients with better performance status 
than in patients with an ECOG score of 1 (77% vs 0%, 
p=0.003). All other analysed miRs did not reveal significant 
correlations with patient characteristics (for detailed 2×2 
contingency tables, see Supplementary Table S1).
Relationship between Pretreatment miR 
Expression and Outcome under Sorafenib 
Treatment
To analyse possible correlations between miR expression and 
clinical outcome under sorafenib treatment, Kaplan-Meier 
analyses and log-rank tests were performed on “high miR 
expression” and “low miR expression” patient groups. We 
found that both PFS and OS rates were better in the “high miR-
224” group than in the “low miR-224” group (PFS, p=0.029; 
OS, p=0.012) (Figs. 2 and 3). The other analysed miRs did not 
show any significant associations with either PFS or OS of 
sorafenib-treated patients in our sample set (Table 3).
An analysis of the impact of clinicopathological charac-
teristics on OS and PFS showed that none of the investi-
gated parameters had a significant association with OS and 
only tumor size showed a marginal correlation with PFS 
(log-rank p=0.08; data not shown).
Although the parameters did not prove to be statistically 
significant, as potentially relevant prognostic factors they 
were forced into the Cox multivariate analysis in order to 
study whether miR-224 is an independent predictor of sur-
vival. Clinicopathological parameters, such as gender, age, 
tumor number, tumor size, Child-Pugh score, ECOG status 
and AFP level, were analysed. Based on this analysis, 
Table 1. Baseline Clinicopathological Characteristics of 
Patients (n=20).
Characteristics
Sample number (%) 
or median [range]
Age (years) 68 [52-82]  
Gender
 Male 16 (80%)
 Female 4 (20%)
Etiology
 Viral 11 (55%)
 Other 9 (45%)
Tumor number
 Single 6 (30%)
 >1 14 (70%)
Tumor size (cm) 5 [1.5-20]
Child-Pugh class
 A 16 (80%)
 B 4 (20%)
ECOG score
 0 13 (65%)
 1 7 (35%)
AFP
 <10ng/ml 7 (35%)
 ≥10ng/ml 13 (65%)
ECOG: Eastern Cooperative Oncology Group; AFP: alpha-fetoprotein.
Table 2. miRNA Expression in Hepatocellular Carcinoma Fine-
needle Aspiration Biopsy Samples Relative to miR-140.
Normalized miR expressions
(median and range)
miR-17-5p 1.91 [0.16 - 10.20]
miR-18a 1.25 [0.07 - 4.89]
miR-21 85.94 [5.13 - 352.95]
miR-34a 3.88 [0.62 - 11.25]
miR-122 173.46 [18.94 - 407.31]
miR-195 2.00 [0.43 - 10.15]
miR-210 1.16 [0.01 - 32.75]
miR-214 0.23 [0.07 - 165.61]
miR-221 0.92 [0.21 - 11.08]
miR-222 2.69 [0.21 - 17.96]
miR-223 4.34 [1.21 - 20.39]
miR-224 1.06 [0.06 - 23.67]
miR-328 0.12 [0.01 - 3.20]
U6 51.71 [0.01 - 1568.32]
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dichotomized miR-224 expression was found to be an inde-
pendent prognostic factor for both OS and PFS (high vs low, 
OS HR=0.11 [95% CI 0.013–0.913] p=0.04, PFS HR=0.125 
[95% CI 0.015–1.034] p=0.05) (Supplementary Table S2).
Discussion
Advanced HCC remains a devastating disease, with dis-
mal prognosis. The introduction of sorafenib (Nexavar®, 
Bayer-Schering Pharma)—the first approved targeted 
therapeutic agent for HCC—represents a milestone in the 
management of this cancer type. Sorafenib is a potent 
multi-kinase inhibitor targeting proliferative and angio-
genic signaling pathways, among others Raf/MEK/ERK 
signaling, vascular endothelial growth factor receptors 2 
and -3 (VEGFR-2,-3) and platelet-derived growth factor 
receptor-β (PDGFR-β) (Wilhelm et al. 2004). Although 
sorafenib was proved to significantly prolong OS, it provides 
Figure 2. Kaplan-Meier curve showing progression-free survival of sorafenib-treated HCC patients according to high and low 
pretreatment miR-224 expression levels.
Figure 3. Kaplan-Meier curve showing overall survival of sorafenib-treated HCC patients according to high and low pretreatment 
miR-224 expression levels.
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only limited clinical benefit due to the heterogeneity of 
the treated patients (Lachenmayer et al. 2010). Moreover, 
predicting the outcome of sorafenib-treated patients is 
still an unmet medical need because there is no consen-
sus regarding the utility of such potential clinical or 
molecular markers (Baek et al. 2011, Pinter 
et al. 2011).
MicroRNAs are key epigenetic regulators of gene 
expression, interfering with both tumorigenic and tumor 
suppressor pathways and thus playing a significant role in 
carcinogenesis. In addition, alterations in the expression of 
miRNAs are thought to bear strong prognostic and predic-
tive potential in malignant diseases such as HCC, among 
others. Their high stability and effective retrieval from 
archival clinical samples make miRNAs ideal biomarkers 
for diagnosis, prognosis and therapy responsiveness 
(Giordano and Columbano 2013). Even small and delicate 
samples, such as FNABs, are suitable for proper miRNA 
analysis, and this is supported by several reports on aspi-
rated samples from the thyroid gland (Kitano et al. 2012), 
pancreas (Ali et al. 2012) and lung (Petriella et al. 2013).
In light of these studies, our aim was to investigate 
miRNA profiles of FNAB samples taken from advanced 
HCC patients and to correlate the obtained results with the 
prognostic data. Because the diagnostic FNABs were taken 
from pretreatment patients who had not received any prior 
surgical, loco-regional or systemic treatment, one could 
assume that the observed miRNA expression profiles truly 
reflect the unaltered molecular background of the tumors.
Our analysis revealed associations between miRNA 
expression and clinicopathological features of the patients. 
High miR-214 expression was associated with smaller tumor 
size, which is in line with previous data, as miR-214 is a 
known tumor suppressor miRNA shown to suppress the 
growth of HCC cells in vitro (Wang et al. 2012). Further, 
high miR-17-5p expression was associated with better ECOG 
performance status in the present study, which appears to 
contradict the findings of others, as elevated miR-17-5p 
expression has been previously correlated with worse prog-
nosis and shortened survival times (Chen et al. 2012). 
However, we did not find a significant association between 
miR-17-5p and the outcome in patients treated with sorafenib.
When further assessing the prognostic significance of 
miRNAs, we found no significant correlations between 
other analysed miRs and prognosis, with the exception of 
miR-224. In vitro studies have previously proposed that 
certain miRNAs sensitize HCC cells to sorafenib: miR-122 
restoration in HCC cells has been shown to significantly 
reduce clonogenic survival and growth upon sorafenib 
treatment (Bai et al. 2009), whereas miR-34a was shown to 
potentiate sorafenib-induced toxicity and apoptosis (Yang 
et al. 2013). In our sample set, neither of these miRs corre-
lated with patient survival.
Intriguingly, pretreatment miR-224 expression proved to 
be associated with OS and PFS under sorafenib treatment. 
miR-224 is frequently upregulated and thus known as an 
oncomir in HCC, targeting cell proliferation, migration, 
invasion and apoptosis (Zhang et al. 2013). Upregulation of 
miR-224 has been described to confer poor prognosis to 
cervical cancer (Shen et al. 2013) and glioma (Lu et al. 
2013) patients. In HCC patients, miR-224 expression did 
not show a correlation with survival; however, when miR-
224 upregulation and simultaneous SMAD4 downregula-
tion were taken into account together, they were associated 
Table 3. Results of Log-rank Statistics with Hazard Ratios of Univariate Cox Regression.
For OS For PFS
 log-rank log-rank
Parameter Category HR [95% CI] p value HR [95% CI] p value
miR-17-5p high 1.09 [0.37 - 3.26] 0.88 1.08 [0.40–2.91] 0.87
miR-18a low 1.57 [0.52 - 4.69] 0.43 1.20 [0.45–3.22] 0.69
miR-21 low 1.03 [0.36 - 2.96] 0.95 0.88 [0.33–2.35] 0.78
miR-34a low 1.84 [0.61 - 5.54] 0.26 1.31 [0.47–3.63] 0.59
miR-122 high 1.15 [0.40 - 3.33] 0.79 1.81 [0.63–5.17] 0.25
miR-195 low 1.42 [0.47 - 4.26] 0.54 1.03 [0.38–2.75] 0.96
miR-210 high 1.70 [0.58 - 4.98] 0.32 1.83 [0.65–5.16] 0.23
miR-214 high 0.62 [0.20 - 1.87] 0.40 0.52 [0.19–1.46] 0.21
miR-221 high 1.92 [0.61 –6.10] 0.29 1.32 [0.47–3.66] 0.58
miR-222 high 2.04 [0.64–6.46] 0.25 1.43 [0.51–3.99] 0.47
miR-223 high 1.25 [0.43–3.62] 0.68 2.15 [0.71–6.45] 0.16
miR-224 high 0.24 [0.07–0.79] 0.01* 0.28 [0.09–0.92] 0.03*
miR-328 high 0.66 [0.22–2.00] 0.47 0.66 [0.24–1.86] 0.42
OS: overall survival; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval. * indicates significance; p<0.05.
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with poorer survival of HCC patients (Wang et al. 2013). 
Although this might appear contradictory to our results, the 
high miR-224 phenotype that we found might also be asso-
ciated with a better responsiveness to sorafenib and thus 
with better clinical outcome upon treatment. Moreover, in 
colon cancer cells, miR-224 confers sensitivity to metho-
trexate (Mencia et al. 2011) and, in HCC cell lines, celastrol 
exerts its antimetastatic effect through the down-regulation 
of miR-224 (Li et al. 2013). Curiously, a bipartite role has 
been described for miR-224 in HCC cell cycle regulation 
because it has the potential to promote both cell prolifera-
tion and apoptotis (Wang et al. 2008; Zhang et al. 2013). 
Thus, on the one hand, high miR-224 might promote tumor 
progression, whereas, on the other hand, it might have the 
potential to render HCC cells susceptible to (drug-induced) 
apoptosis.
Among the several putative miR-224 targets are PDGFR-α 
and PDGFR-β (Dweep et al. 2011; Murakami et al. 2006). 
Interestingly, the expression of both molecules was shown to 
predict poor prognosis (Chen et al. 2011) and shorter OS in 
patients with resected HCC (Patel et al. 2011). Moreover, 
PDGFR-β is a known target of sorafenib (Wilhelm et al. 
2004). Intriguingly, in a previous study with an experimental 
design similar to ours, low PDGFR-β expression of biopsy 
specimens from sorafenib-treated patients was shown to be 
associated with longer OS (Chu et al. 2013). This is in line 
with our results, where we also found significantly prolonged 
OS of patients with high expression of miR-224, the potential 
negative regulator of PDGFR-β.
The limitations of this study are the relatively small sam-
ple size, the lack of non-tumorous control and the retrospec-
tive nature of the analysis. Larger cohorts and prospective 
studies would be needed to validate the utility of this 
approach. Nonetheless, this study supports the potential use 
of miRNAs as biomarkers and predictors of clinical response 
to therapy. miRNAs have already been suggested by other 
authors to influence or predict sorafenib sensitivity (Xia et al. 
2013; Zhou et al. 2011); therefore, these miRNAs should also 
be tested on clinical samples. Our approach is a promising 
one for the further identification of miRNAs that can predict 
patient responsiveness to therapy. To the best of our knowl-
edge, our study is the first to evaluate the miRNA profiles of 
FNAB samples harvested from HCC patients. Pretreatment 
microRNA profiling, particularly for miR-224 expression, 
might serve as an ancillary tool for the better assessment of 
expected survival of patients under sorafenib treatment.
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